{"id":"W2588916311","doi":"10.1056/nejmoa1613683","title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":3390,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Janssen Pharmaceuticals; National Cancer Institute; Genentech; Cilag; Astellas Pharma; Sanofi; Exelixis; Eisai; BioClinica; Takeda Oncology; Amgen; Pfizer; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Hazard ratio; Internal medicine; Docetaxel; Chemotherapy; Oncology; Population; Gastroenterology; Urology; Cancer; Confidence interval; Surgery; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001028999,0.0004847777,0.001392458,0.0004369154,0.0002452439,0.0006168199,0.0004780559,0.0006837255,0.002674126],"category_scores_gemma":[0.000898902,0.0001958528,0.0007471983,0.0003271648,0.0003406188,0.0004067993,0.0002465465,0.00145711,0.0003618911],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006370455,"about_ca_system_score_gemma":0.0006361855,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004398119,"about_ca_topic_score_gemma":0.001152119,"domain_scores_codex":[0.999691,0.0001436984,0.00002244075,0.00005634604,0.0000399573,0.00004663221],"domain_scores_gemma":[0.9994845,0.0001438473,0.0001086135,0.0000306171,0.00002092788,0.0002112892],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.642548,0.02225179,0.02090425,0.00252723,0.002359943,0.0003551948,0.0002613484,0.00346845,0.02589988,0.0004643668,0.002623434,0.276336],"study_design_scores_gemma":[0.596661,0.3337745,0.04872048,0.0003212058,0.001279929,0.001012099,0.00008553394,0.003439485,0.006297708,0.0005100813,0.007858856,0.00003897943],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889182,0.008352783,0.0002907224,0.0002944833,0.0001621871,0.0007044865,0.0001735784,0.00003504302,0.001068404],"genre_scores_gemma":[0.9951525,0.002519506,0.0004497198,0.0003331126,0.0001302603,0.0006315175,0.0002323495,0.000005366526,0.0005456478],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002674126,"threshold_uncertainty_score":0.008945882,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03598082071968254,"score_gpt":0.340225763948257,"score_spread":0.3042449432285744,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}